The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS).
William D. Tap
No relevant relationships to disclose
Brian Andrew Van Tine
No relevant relationships to disclose
Anthony D. Elias
No relevant relationships to disclose
Michael B. Livingston
No relevant relationships to disclose
Mark Agulnik
No relevant relationships to disclose
Matthew M. Cooney
No relevant relationships to disclose
Bartosz Chmielowski
No relevant relationships to disclose
Andrew Jacob Brenner
No relevant relationships to disclose
Gregory K. Pennock
Honoraria - Bristol-Myers Squibb; Merck
Neeta Somaiah
No relevant relationships to disclose
Long H. Dang
No relevant relationships to disclose
Gary G. Tian
No relevant relationships to disclose
Robin Lewis Jones
No relevant relationships to disclose
Scott H. Okuno
No relevant relationships to disclose
Nick Loizos
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Johannes Nippgen
Employment or Leadership Position - ImClone Systems
Gary K. Schwartz
No relevant relationships to disclose